Provided by Tiger Trade Technology Pte. Ltd.

Myriad Genetics

3.13
-0.0950-2.95%
Volume:2.29M
Turnover:6.96M
Market Cap:298.75M
PE:-2.60
High:3.22
Open:2.95
Low:2.92
Close:3.22
52wk High:8.59
52wk Low:2.74
Shares:95.60M
Float Shares:79.40M
Volume Ratio:1.62
T/O Rate:2.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2031
EPS(LYR):-3.9514
ROE:-32.54%
ROA:-8.59%
PB:0.98
PE(LYR):-0.79

Loading ...

Myriad Genetics Q2 FY26 Operating Loss Narrows to $38.9 Million; Revenue Drops 11% to $190.7 Million

Reuters
·
Jul 31

Myriad Genetics Q2 Adj. EPS $(0.25) Misses $(0.06) Estimate, Sales $190.700M Miss $206.029M Estimate

Benzinga Earnings
·
Jul 31

Myriad Genetics Q2 Revenue USD 190.7 Million Vs. IBES Estimate USD 206 Million

Reuters
·
Jul 31

Myriad Genetics - Suspends Full-Year 2026 Adj Ebitda Guidance

THOMSON REUTERS
·
Jul 31

Myriad Genetics Outlook FY Revenue USD 770-790 Million

THOMSON REUTERS
·
Jul 31

Myriad Genetics Q2 Gross Margin 66.6%

THOMSON REUTERS
·
Jul 31

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

THOMSON REUTERS
·
Jul 31

Myriad Genetics Inc Expected to Post a Loss of 6 Cents a Share - Earnings Preview

Reuters
·
Jul 29

Centene Appoints Cressey’s Paul Diaz to Board as Burdick Retires

Reuters
·
Jul 28

Myriad Genetics Schedules Q2 Earnings Conference Call

Reuters
·
Jul 23

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

GlobeNewswire
·
Jul 23

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

GlobeNewswire
·
Jul 21

Myriad Says Meta-analysis Supports Prognostic Performance of Prolaris Biopsy Test in Localized Prostate Cancer

Reuters
·
Jul 02

Sera Prognostics Names Former Myriad Genetics CEO Mark Capone to Board

Reuters
·
Jul 01

Myriad Genetics Announces Resignation of Board Member Skovronsky

TIPRANKS
·
Jun 23

Myriad Genetics says MONITOR-Breast study supports Precise MRD ctDNA test in neoadjuvant monitoring

Reuters
·
Jun 23

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

GlobeNewswire
·
Jun 23

Myriad Genetics director Daniel Skovronsky resigns from board

Reuters
·
Jun 23

3 Penny Stocks With Market Caps Over $400M To Consider

Simply Wall St.
·
Jun 22

Living Longer Is Big Business. These Stocks Will Benefit. -- Barrons.com

Dow Jones
·
Jun 19